- Details
- Oliver Sartor interviews Chuck Conroy about Nucleus RadioPharma’s role in radiopharmaceutical manufacturing and distribution. Mr. Conroy explains that Nucleus RadioPharma aims to support both small and large pharmaceutical companies in developing and delivering radioligand therapies. The company is building extensive manufacturing facilities across the US, with plans to create more capacity than c...
|
- Details
- Sergio Calvo discusses GE's role in theranostics, emphasizing their broad portfolio spanning cyclotrons, radiosynthesis modules, and imaging devices. He highlights GE's recent acquisition of MIM Software to enhance flexibility in image analysis for diverse radioligand therapies. Mr. Calvo predicts significant growth in the field, expecting a twentyfold increase in patient treatments within a decad...
|
- Details
- Oliver Sartor interviews John Valliant about the potential of radiopharmaceuticals in cancer treatment. Dr. Valliant discusses the advantages of targeted radiation therapy, particularly using Actinium-225, highlighting its efficacy and potential for combination therapies. He emphasizes the unique ability of radiopharmaceuticals to combine imaging and treatment, allowing for better patient selectio...
|
- Details
- Oliver Sartor interviews Anna Karmann about the potential of radiopharmaceuticals in cancer treatment. Dr. Karmann discusses the advantages of Lead-212, highlighting its alpha-emitting properties, short half-life, and potential for frequent dosing strategies. She emphasizes the unique benefits of Lead-212, including its synergy with the immune system and logistical advantages in drug delivery. Dr....
|
- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- Oliver Sartor discusses radiopharmaceuticals with Germo Gericke. Dr. Gericke emphasizes the potential of targeted radioligand therapies, particularly for advanced cancers. He explores various isotopes, including Lutetium, Terbium, and Actinium, highlighting Actinium's promise in preclinical studies. Dr. Gericke discusses ideal target characteristics and Ariceum's innovative approach of targeting i...
|
- Details
- Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
|
- Details
- Oliver Sartor speaks with Michael Schultz about advances in radiopharmaceuticals for cancer treatment. Dr. Schultz discusses the advantages of using alpha-particle emitters, particularly lead-212, for targeted cancer therapy. He explains the rationale behind choosing lead-212, including its short half-life and the ability to use lead-203 for imaging. Dr. Schultz addresses distribution challenges a...
|
- Details
- Oliver Sartor speaks with Philip Kantoff about the future of radiopharmaceuticals in cancer treatment. Dr. Kantoff discusses the rationale behind using antibody-based approaches for PSMA-targeted therapies, particularly with actinium-225, citing better cancer cell retention and reduced toxicity to salivary and lacrimal glands compared to small molecules. He highlights promising early results from...
|
- Details
- Oliver Sartor speaks with Emanuele Ostuni about ARTBIO’s focus on radiopharmaceuticals, particularly lead-212. Dr. Ostuni explains ARTBIO’s choice of lead-212 for its short half-life, which better matches the biological half-lives of targeting ligands. He discusses the manufacturing and distribution challenges associated with short-lived isotopes and outlines ARTBIO’s approach to developing a netw...
|
